Actively Recruiting
Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Care (NI-AKI)
Led by Ramsay Générale de Santé · Updated on 2025-10-02
150
Participants Needed
1
Research Sites
37 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Among all patients admitted to intensive care, it is estimated that more than half of them are exposed during their stay to acute renal failure (ARF). Impacting the vital prognosis to short term, the occurrence of renal failure is not without consequences in intensive care survivors, presenting an increased risk of death mainly mediated by an excess risk with regard to chronic kidney disease and/or certain cardiovascular pathologies. Malnutrition, particularly vitamin deficiency, has already been reported as a risk factor for AKI. Studies on two models (animal and human) have recently highlighted the importance of NAD+ production failure in the onset of renal failure. NAD+ synthesis can be done from tryptophan or via a salvage pathway from vitamin PP. In a phase 2 study in patients undergoing cardiac surgery, vitamin B3 supplementation was accompanied by a reduction in the occurrence of AKI and a limitation of the duration / intensity of renal dysfunction. This innovative research aims to identify an alteration in the metabolic pathway of NAD+ production as a risk factor for AKI in intensive care patients. This would be the first study to address this issue in this specific population. The main objective of this research is to describe the association between the urinary Quinolinate/Tryptophan ratio on admission and the occurrence of acute renal failure in patients admitted to intensive care unit.
CONDITIONS
Official Title
Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Care (NI-AKI)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient, male or female aged over 18
- Patient admitted to intensive care for a reason with a high risk of acute renal insufficiency: shock, sepsis, cardio-circulatory arrest, post-operative unscheduled surgery, post-operative cardiac surgery
- Patient with normal renal function on admission
- Patient affiliated to or beneficiary of a social security scheme
- Patient having been informed and having given his/her free, informed and written consent
You will not qualify if you...
- Minor patient
- History of chronic kidney disease
- History of kidney transplant
- Admission for a reason with a low risk of acute renal insufficiency (neuroresuscitation, voluntary drug intoxication with anxiolytics, antidepressants, psychotropic drugs)
- Acute non-infectious respiratory failure
- Scheduled surgery other than cardiac surgery
- Patient hospitalized without consent
- Patient in a period of exclusion due to another research still in progress at the time of inclusion
- Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
- Pregnant, breastfeeding or parturient woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Privé de l'Ouest Parisien
Trappes, France, 78190
Actively Recruiting
Research Team
M
Matthieu JAMME, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here